A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer

Trial Profile

A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf) in Combination With an mTOR Inhibitor, Everolimus (Afinitor) or Temsirolimus (Torisel), in Subjects With Advanced Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Temsirolimus (Primary) ; Vemurafenib (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2016 Interim results (n=20) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 24 May 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top